Myriad Genetics (MYGN) Tops Q1 EPS by 3c ; Offers Guidance
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $3.20 -0.62%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $195.9 million versus the consensus estimate of $200.9 million.
GUIDANCE:
Myriad Genetics sees FY2025 EPS of ($0.02)-$0.02, versus the consensus of $0.08. Myriad Genetics sees FY2025 revenue of $807-823 million, versus the consensus of $916 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises
- BofA says CTA Treasury shorts stable, euro short-cover risk rises
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
